| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Marvel Biosciences Corp: Marvel Biosciences talks Shank 3 preliminary data | 2 | Stockwatch | ||
| Di | Marvel Biosciences Corp.: Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours | 2 | GlobeNewswire (USA) | ||
| Di | Marvel Biosciences shares preliminary MB-204 autism mouse-study data | - | The Market Online Canada | ||
| 19.10. | Marvel Biosciences Corp: Marvel Biosciences picks CMAX for MB-204 phase 1 trial | 1 | Stockwatch | ||
| 19.10. | Marvel Biosciences Corp.: Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site | 1 | GlobeNewswire (USA) | ||
| 09.10. | Marvel Biosciences Corp: Marvel Biosciences 10,654,298-share private placement | 1 | Stockwatch | ||
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.10. | Marvel Biosciences Corp.: Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model | 192 | GlobeNewswire (Europe) | CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 06.10. | Marvel Biosciences Corp: Marvel Biosciences signs LOI with Novatech for trial | 3 | Stockwatch | ||
| 06.10. | Marvel Biosciences Corp.: Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update | 203 | GlobeNewswire (Europe) | CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 30.09. | Marvel Biosciences closes private placement for C$1.6M | 3 | Investing.com | ||
| 30.09. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million | 660 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 29, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August... ► Artikel lesen | |
| 17.09. | Marvel Biosciences announces non-brokered private placement for up to $3M | 1 | Seeking Alpha | ||
| 17.09. | Marvel Biosciences plant Privatplatzierung von bis zu 3 Mio. C$ | 1 | Investing.com Deutsch | ||
| 17.09. | Marvel Biosciences plans private placement of up to C$3M | 1 | Investing.com | ||
| 17.09. | Marvel Biosciences Corp.: Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million | 631 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August... ► Artikel lesen | |
| 10.09. | Marvel Biosciences Corp: Marvel Biosciences extends placement to Sept. 14 | 1 | Stockwatch | ||
| 09.09. | Marvel Biosciences gets approval to extend private placement deadline | 1 | Investing.com | ||
| 09.09. | Marvel Biosciences Corp.: Marvel Biosciences Announces Extension to Closing Date of Private Placement | 514 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture... ► Artikel lesen | |
| 20.08. | Marvel Biosciences Corp: Marvel Biosciences expands financing to Quebec | 2 | Stockwatch | ||
| 19.08. | Marvel Biosciences Corp.: Marvel Biosciences Expands Private Placement to Quebec | 555 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MBX BIOSCIENCES | 55,94 | 0,00 % | Citizens reiterates MBX Biosciences stock rating on GLP agonist data | ||
| ERASCA | 15,655 | -0,03 % | Erasca GAAP EPS of -$0.15 misses by $0.01 | ||
| TANGO THERAPEUTICS | 25,500 | 0,00 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| VIR BIOTECHNOLOGY | 9,970 | +0,10 % | Vir Biotechnology: HDV-Daten lassen Aktie explodieren | Vir Biotechnology sorgt mit gleich zwei positiven Nachrichten im Bereich Hepatitis Delta für Aufsehen. Sowohl die ersten Ergebnisse der zulassungsrelevanten Phase-3-Studie als auch erweiterte Phase-2-Daten... ► Artikel lesen | |
| CG ONCOLOGY | 74,36 | -0,05 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,140 | -0,07 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,68 | -0,14 % | Praxis Precision Medicines stellt Markteinführungspläne für zwei Medikamentenkandidaten vor | ||
| RELAY THERAPEUTICS | 18,090 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,810 | +0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,690 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ABSCI | 8,440 | -0,12 % | Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 start | ||
| PRIME MEDICINE | 4,270 | 0,00 % | Prime Medicine closes $143.7M public offering at $3.50/share | ||
| AMYLYX PHARMACEUTICALS | 30,300 | +0,03 % | Amylyx: Avexitide-Studie erreicht primären Endpunkt bei postbariatrischer Hypoglykämie | ||
| PARABILIS MEDICINES | 28,430 | 0,00 % | Liberty Defense zahlt Darlehen über 2,45 Millionen US-Dollar an Parabilis vollständig zurück |